Before you sell to, join or invest in ADAPTIN BIO, INC.
MentionFox check on ADAPTIN BIO, INC.: only 1 source on file so far (checked 5 November 2026). Run a full check before you rely on it. mentionfox.com/c/funding/adaptin-bio-inc-form-d-25000001
Check ADAPTIN BIO, INC. before you sell to, join or invest Free, no sign-up: every record on file, each linked to its source.
What do you want to do about ADAPTIN BIO, INC.?
Based on the record MentionFox holds for this company. No flag is not a clearance.
ADAPTIN BIO, INC. filed a Form D with the Securities and Exchange Commission on 2025-02-26.
ADAPTIN BIO, INC. filed a Form D notice of an exempt securities offering with the SEC on February 26, 2025. ADAPTIN BIO, INC. trades on OTC as APTN; it was formerly Unite Acquisition 1 Corp. The filing reports $13.08M sold. Its industry group is Biotechnology. It names Michael Roberts (President and Chief Executive Officer), Patrick Gallagher (Director), J. Riehle (Director) (SEC Form D, February 26, 2025).
In its own words: “Our key discovery Brain Bispecific T cell Engager (BRiTE) hitchhiking drug delivery platform A unique combination of novel T cell engager + specifically manipulated polyclonal T cells Learn More Benefit at.” (adaptinbio.com, checked November 1, 2026)
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like ADAPTIN BIO, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-02-26 · the record
Pitching, partnering or investing alongside them? See who really runs and owns ADAPTIN BIO, INC.
Free to see. No signup.
More on the people and the money behind ADAPTIN BIO, INC., from the filings we hold.
Laidlaw & Company (UK) Ltd. received sales compensation on this raise and on 1 other raise we hold, nearest in date first:
Get an email when ADAPTIN BIO, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when ADAPTIN BIO, INC. raises, hires or launches. No email unless you switch it on.
Watch ADAPTIN BIO, INC. →Get the full cited report on ADAPTIN BIO, INC.
What the filing shows about ADAPTIN BIO, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ADAPTIN BIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives ADAPTIN BIO, INC.'s address as 3540 Toringdon Way, Suite 200, #250, Charlotte, NC 28277.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for ADAPTIN BIO, INC. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
ADAPTIN BIO, INC. is a registered filer with the SEC (CIK 1938571) and has filed since 2025-02-26. 5 filings are on record, the latest on 2026-06-22.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
ADAPTIN BIO, INC.'s Form D of 2025-02-26 names Michael Roberts, Patrick Gallagher, J. Riehle and 4 more as its officers, directors or promoters.
Its new offerings report $14.08M sold across 2 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 765 filings in Biotechnology, totalled by week.
Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.
On the filing as: Executive Officer, Director.
Michael Roberts is named as President and Chief Executive Officer on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
Patrick Gallagher is named as Director on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
J. Riehle is named as Director on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
Anthony Zook is named as Director on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
On the filing as: Executive Officer.
L. Hewitt is named as Chief Development Officer on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
On the filing as: Executive Officer.
Timothy Maness is named as Chief Financial Officer on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
On the filing as: Executive Officer, Director.
Simon Pedder is named as Executive Chairman on the Form D that ADAPTIN BIO, INC. filed with the SEC on 26 February 2025, one of 7 people that filing names.
7 people named on the filing — 4 holding an executive role and 3 as directors only.
Named as of the 2025-02-26 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about ADAPTIN BIO, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on ADAPTIN BIO, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ADAPTIN BIO, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist ADAPTIN BIO, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind ADAPTIN BIO, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for ADAPTIN BIO, INC.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/adaptin-bio-inc-form-d-25000001